CAMBRIDGE, Mass.--(BUSINESS WIRE)--Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today that it has completed the purchase of a commercial-scale radiopharmaceutical manufacturing facility located in Denton, Texas, effective October 1, 2007. Molecular Insight purchased the facility from NeoRx Manufacturing Group, Inc., a wholly owned subsidiary of Poniard Pharmaceuticals, Inc., for a cost of three million dollars. The Company originally announced the transaction in May 2007, pending final due diligence.
